Boston Scientific Corp reported two material capital moves Monday that together aim to reshape its near-term capital deployment and strategic exposure to transcatheter aortic valve replacement (TAVR) technology.
The company's shares rose 2.1% in premarket trading after Boston Scientific disclosed a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank and a separate $1.5 billion investment in MiRus LLC.
Details of the accelerated repurchase
The ASR with JPMorgan Chase Bank covers $2 billion of Boston Scientific common stock and is part of the firms previously announced $5 billion share repurchase authorization. Under the terms provided, Boston Scientific will receive approximately 30.4 million shares based on the May 15 closing price of $52.68, representing 80% of the repurchase price. Final settlement of the ASR is expected by June 30, 2026, and $3 billion will remain available under the broader authorization after this transaction.
Boston Scientific stated that the accelerated share repurchase is expected to add $0.02 to adjusted earnings per share for the full year 2026, a contribution that the company describes as accretive to the guidance issued on April 22, 2026.
Investment in MiRus and the SIEGEL TAVR system
Separately, Boston Scientific announced a $1.5 billion investment to acquire about a 34% equity stake in MiRus LLC, a privately-held developer of cardiovascular and orthopedic treatments. The investment provides Boston Scientific with an exclusive option to acquire the MiRus TAVR system, subject to additional cash payments and the achievement of specified milestones.
The MiRus-developed SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement system is described as the first nickel-free, balloon-expandable TAVR valve and employs a proprietary rhenium alloy. Design features called out by the company include dry porcine tissue leaflets and a nitric oxide-coated rhenium frame. According to the disclosure, all sizes of the SIEGEL valve can be delivered through an 8 French expandable sheath, which the company notes is approximately 50% smaller than current commercially available TAVR delivery sheaths.
Boston Scientific may exercise its option to acquire the MiRus TAVR business by making additional aggregate cash payments totaling $3 billion following the attainment of certain clinical and regulatory milestones. The company also said the MiRus investment is expected to be immaterial to adjusted earnings per share for Boston Scientific in 2026. The SIEGEL TAVR system remains investigational and is not approved for commercial distribution.
Market reaction and positioning
The combined announcement - an immediate $2 billion ASR and a strategic equity stake in a TAVR developer with an option for future acquisition - corresponded with a 2.1% premarket lift in Boston Scientific shares. The company retains $3 billion under its repurchase authorization following the ASR, and the MiRus agreement creates an avenue to potentially add a nickel-free, balloon-expandable TAVR technology to its portfolio if milestones are met and the option is exercised.